A Mechanism-Driven Treatment for Chronic Lymph... - CLL Support

CLL Support

23,088 members39,645 posts

A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia?

Cllcanada profile image
CllcanadaTop Poster CURE Hero
1 Reply

Editorial

nejm.org/doi/pdf/10.1056/NE...

Also published data on early ibrutinib trial...

'The New England Journal of Medicine (NEJM) has published data online about the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a monotherapy in patients with chronic lymphocytic leukemia (CLL). Results from a Phase 1b/2 study show that ibrutinib is well tolerated and produced durable responses at both dose levels studied in patients with relapsed/refractory CLL or small lymphocytic lymphoma (SLL). Promising results were seen in patients with advanced disease and in patients with high risk disease as defined by clinical or genetic features, such as deletion of part of chromosome 17 (del17p).'

nejm.org/doi/pdf/10.1056/NE...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
AussieNeil profile image
AussieNeilPartnerAdministrator

And here is Dr Sharman's blog on the paper and editorial, plus a brief mention of his experiences with early patients on the trial:

cll-nhl.com/2013/06/ibrutin...

Drs Sharman, Byrd and O'Brien, who will be familiar to this community, were among the paper's authors.

It is worth reading the Editorial paragraph starting at the end of the first page commencing:

"This study triggers a number of considerations. The complete remission rate with ibrutinib appears to be low. The activity of this agent will need to be assessed in patients who have received less previous treatment...."

As Dr Sharman says in his final paragraph:

"There is never a good time to get CLL, but if you had to pick one, now would be the time to get it! Lots of cool change coming. "

Neil

Not what you're looking for?

You may also like...

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

From the New England Journal of Medicine 10th December 2023 "The CLL treatment landscape has...

Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...

New research study reported in NEJM: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Found this to be a good news article. I know some will say study was funded heavily by drug...

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Jan 19,...

BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

It gets kinda technical but this is some great research on ibrutinib resistance by Dr. Woyach....